ReviewCurrent oncology (Toronto, Ont.)2025
Borderline Phyllodes Breast Tumors: A Comprehensive Review of Recurrence, Histopathological Characteristics, and Treatment Modalities.
Review in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Diagnostic value of a multiparametric magnetic resonance imaging-based nomogram incorporating apparent diffusion coefficient in preoperative differentiation of phyllodes tumors from breast cancer: a retrospective study.Quantitative imaging in medicine and surgery · 2026Article
- Breast tumor with giant phyllodes: a case report.Gland surgery · 2026Article
- Integrated multi-regional multiomic profiling of breast phyllodes tumours reveals peritumoural immune activation and stromal remodelling.Clinical and translational medicine · 2026Article
- Rapidly Progressive Giant Malignant Phyllodes Tumor of the Breast: A Surgical Challenge.Cureus · 2026Article
- Giant Malignant Phyllodes Tumor with Secondary Thyroid Involvement.Diseases (Basel, Switzerland) · 2026Article
- Recurrent Malignant Phyllodes Tumor of the Breast: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phyllodes tumors account for 2-3% of all fibroepithelial breast tumors and less than 1% of all breast cancers. These tumors are categorized into benign, borderline, or malignant based on cellular atypia, mitotic activity, and stromal overgrowth. Surgical excision with clear margins, ideally greater than 1 cm, is the primary treatment for phyllodes tumors to ensure effective local control. Preoperative diagnosis is challenging due to the clinical and radiological similarities between phyllodes tumors and fibroadenomas. The efficacy and role of adjuvant treatments remain subjects of ongoing debate and investigation. Borderline phyllodes tumors exhibit biological characteristics that straddle the line between benign and malignant, presenting significant clinical and surgical management challenges. Given the rarity of this specific subgroup and the ambiguity of the risk of recurrence or progression to malignant phyllodes, this narrative review aims to provide a comprehensive overview of the recurrence risk associated with these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.